MedTrace Logo

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

NCT04293523 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 427

Last updated 2026-03-19

No results posted yet for this study

Summary

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Conditions

Interventions

DRUG

ELOCTA

Extended half-life factor VIII product

Sponsors & Collaborators

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Study Physician · Swedish Orphan Biovitrum AB

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • Czechia
  • Estonia
  • Finland
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Oman
  • Saudi Arabia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04293523 on ClinicalTrials.gov